Company: G
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0001398659-25-000035
Chunk: 109

Company: Genpact LTD
Filing Date: 2025-03-03
Form: 10-K
Item: Item 7
Chunk 109
---
 2024, compared to $78.9 million in 2023. Cash used for payments (net of sales proceeds) for the purchase of property, plant and equipment and internally generated intangible assets was $23.8 million higher in 2024 than in 2023. Additionally, we invested $23.4 million in short-term investments (term deposits) in 2024 but made no similar investments in 2023. Cash used for the divestiture of a business classified as held for sale was $19.5 million, and cash used for business combinations was $0.7 million in 2023, while no corresponding payments were made in 2024. For additional information, see Note 7—“Assets and liabilities held for sale” to our consolidated financial statements under Part IV, Item 15—“Exhibits and Financial Statement Schedules.” 

Cash flows used for financing activities.  Our net cash used for financing activities was $424.8 million in 2024, compared to $483.0 million in 2023. This change was primarily due to (i) lower repayment of borrowings (net of proceeds), including finance lease obligations, amounting to $58.6 million in 2024 compared to $173.0 million in 2023 and (ii) a $2.4 million payment of earn-out consideration in 2023 with no corresponding payment in 2024. This increase in cash flow from financing activities was partially offset by (i) lower proceeds from the issuance of common shares under our stock-based compensation plans of $17.2 million in 2024 compared to $39.5 million in 2023, (ii) higher payments for stock repurchased and retired (including payments of expenses and taxes related to stock repurchase activity) of $252.7 million in 2024 compared to $225.5 million 2023, (iii) higher dividend payments, amounting to $108.5 million in 2024 compared to $100.0 million in 2023, and (iv) higher payments for the net settlement of stock-based awards, amounting to $22.3 million in 2024 compared to $21.5 million in 2023.

Financing Arrangements (Credit facility)

In December 2022, we entered into an amended and restated credit agreement (the "2022 Credit Agreement") with Genpact USA, Inc. (“Genpact USA”), Genpact Global